Nevoid Basal Cell Carcinoma Syndrome

• Nevoid Basal Cell Carcinoma Syndrome (NBCCS), also known as Gorlin syndrome, is a rare, inherited genetic disorder.
• It is primarily characterized by a predisposition to multiple basal cell carcinomas (BCCs) and jaw cysts.
• The syndrome is caused by mutations in the PTCH1 gene, inherited in an autosomal dominant pattern.
• Diagnosis relies on specific clinical criteria and can be confirmed by genetic testing.
• Management involves regular surveillance for tumors and a multidisciplinary approach to address various manifestations.

What is Nevoid Basal Cell Carcinoma Syndrome?

Nevoid Basal Cell Carcinoma Syndrome (NBCCS), often referred to as Gorlin syndrome, is a rare, inherited genetic disorder. It is characterized by a wide range of developmental abnormalities and an increased risk of developing various tumors, most notably multiple basal cell carcinomas (BCCs) of the skin. These BCCs often appear early in life, sometimes even during childhood or adolescence, and can be numerous. The syndrome also commonly leads to the formation of odontogenic keratocysts in the jaw, which are benign but can be aggressive and recurrent.

This condition is caused by a mutation in the Patched-1 (PTCH1) gene, which plays a critical role in the Hedgehog signaling pathway, essential for cell growth and differentiation. NBCCS is inherited in an autosomal dominant pattern, meaning only one copy of the altered gene in each cell is sufficient to cause the disorder. According to the National Organization for Rare Disorders (NORD), Gorlin syndrome affects approximately 1 in 31,000 to 1 in 160,000 individuals worldwide, highlighting its rarity.

Recognizing Symptoms and Causes of Gorlin Syndrome

The underlying Nevoid Basal Cell Carcinoma Syndrome causes stem from germline mutations in the PTCH1 gene, located on chromosome 9q22.3. This gene acts as a tumor suppressor, and its mutation leads to uncontrolled cell growth and development, manifesting in the diverse symptoms associated with the syndrome. While most cases are inherited, approximately 30-50% of individuals with NBCCS have a new (de novo) gene mutation, meaning they are the first in their family to be affected.

The Nevoid Basal Cell Carcinoma Syndrome symptoms are highly variable, even among affected individuals within the same family. Key clinical features often include:

• Basal Cell Carcinomas (BCCs): Multiple, often hundreds, appearing on sun-exposed and non-sun-exposed areas, typically starting in adolescence or early adulthood.
• Odontogenic Keratocysts: Cysts in the jawbones that can be aggressive and lead to jaw expansion and displacement of teeth.
• Skeletal Abnormalities: Common findings include bifid ribs (forked ribs), vertebral anomalies, scoliosis, and short fourth metacarpals.
• Palmar and Plantar Pits: Small, shallow depressions on the palms of the hands and soles of the feet.
• Macrocephaly: An abnormally large head circumference.
• Facial Features: Prominent forehead, widely spaced eyes (hypertelorism), and broad nasal root.
• Neurological Manifestations: Medulloblastoma (a type of brain tumor) can occur, particularly in childhood, though it is relatively rare.
• Ovarian Fibromas: Benign tumors of the ovaries, more common in females.

Diagnosing and Treating Gorlin Syndrome

The Gorlin syndrome diagnosis and treatment pathway typically begins with a thorough clinical evaluation based on established diagnostic criteria, which include both major and minor features of the syndrome. Genetic testing for mutations in the PTCH1 gene provides definitive confirmation. Early diagnosis is crucial for implementing proactive surveillance and management strategies to mitigate potential complications.

Treatment for Gorlin syndrome is primarily focused on managing its various manifestations and preventing serious complications. This involves a multidisciplinary approach with specialists such as dermatologists, oral surgeons, oncologists, and geneticists. Key aspects of management include:

Ongoing research continues to explore targeted therapies and improved management strategies for individuals living with Nevoid Basal Cell Carcinoma Syndrome, aiming to enhance quality of life and long-term outcomes.